Invest now
Ajanta Pharma share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹3,503.00(-0.20%)August 11, 2026 15:27:25 PM IST
- NSE
- BSE
- Vol : 94.28 K (NSE + BSE)Last 20 day avg : 118.54 K
Ajanta Pharma is trading -0.20% lower at Rs 3,503.00 as compared to its last closing price. Ajanta Pharma has been trading in the price range of 3,582.00 & 3,498.30. Ajanta Pharma has given 26.63% in this year & -0.22% in the last 5 days. Ajanta Pharma has TTM P/E ratio 37.68 as compared to the sector P/E of 32.78.There are 15 analysts who have initiated coverage on Ajanta Pharma. There are 6 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 334.22 Crores in its last quarter.Listed peers of Ajanta Pharma include Sun Pharmaceutical Industries (-0.65%), Divi's Laboratories (3.17%), Torrent Pharmaceuticals (-0.54%).The Mutual Fund holding in Ajanta Pharma was at 18.10% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Ajanta Pharma was at 7.68% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 11 Aug 2026, 07:45 PM IST
- BetaLow volatility0.75Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.06The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.80Annual dividends as a percentage of the stock price.
- P/BHigher than historical values9.63The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values38.41Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.70The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Ajanta Pharma News
Ajanta Pharma Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,940.00 | -0.65 | 4,65,460.02 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 8,537.00 | 3.17 | 2,26,630.53 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,888.90 | -0.54 | 1,85,951.39 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,462.00 | 0.14 | 1,18,106.99 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,180.00 | 5.29 | 1,17,705.45 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allAjanta Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-30 | Quarterly Results & Interim Dividend |
| 2026-05-05 | Audited Results |
| 2026-01-30 | Quarterly Results |
| 2025-11-03 | Quarterly Results & Interim Dividend |
| 2025-07-28 | Quarterly Results & Others |
About the company Ajanta Pharma
- IndustryBiotechnology & Drugs
- ISININE031B01049
- BSE Code532331
- NSE CodeAJANTPHARM
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
Ajanta Pharma Share Price FAQs
Ajanta Pharma is trading at 3503.00 as on Tue Aug 11 2026 09:57:25. This is -0.20% lower as compared to its previous closing price of 3509.85.
The market capitalization of Ajanta Pharma is 43771.27 Cr as on Tue Aug 11 2026 09:57:25.
The average broker rating on Ajanta Pharma is Buy. The breakup of analyst rating is given below -
- 6 analysts have given a strong buy rating
- 4 analysts have given a buy rating
- 3 analysts have given a hold rating
- 2 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Ajanta Pharma is 3598.40 whereas the 52 wk low is 2335.00
Ajanta Pharma can be analyzed on the following key metrics -
- TTM P/E: 37.68
- Sector P/E: 32.78
- Dividend Yield: 0.80%
- D/E ratio: -
Ajanta Pharma reported a net profit of 1056.00 Cr in 2026.
The Mutual Fund Shareholding was 18.10% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Ajanta Pharma QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.